New directions for emerging therapies in acute myeloid leukemia: the next chapter.

Blood Cancer J · 2020 · PMC7599225 · PMID 33127875

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

This suggests that similar to molecular mutation heterogeneity, there may be significant immune heterogeneity in AML, and that patient selection using immune biomarkers may help identify patients most likely to benefit from this regimen, thereby optimizing the risk-benefit ratio with such immune therapies in AML.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.